Derivation and validation of a predictive mortality model of in-hospital patients with Acinetobacter baumannii nosocomial infection or colonization
- PMID: 38607579
- PMCID: PMC11178602
- DOI: 10.1007/s10096-024-04818-7
Derivation and validation of a predictive mortality model of in-hospital patients with Acinetobacter baumannii nosocomial infection or colonization
Abstract
Purpose: Acinetobacter baumannii (Ab) is a Gram-negative opportunistic bacterium responsible for nosocomial infections or colonizations. It is considered one of the most alarming pathogens due to its multi-drug resistance and due to its mortality rate, ranging from 34 to 44,5% of hospitalized patients. The aim of the work is to create a predictive mortality model for hospitalized patient with Ab infection or colonization.
Methods: A cohort of 140 sequentially hospitalized patients were randomized into a training cohort (TC) (100 patients) and a validation cohort (VC) (40 patients). Statistical bivariate analysis was performed to identify variables discriminating surviving patients from deceased ones in the TC, considering both admission time (T0) and infection detection time (T1) parameters. A custom logistic regression model was created and compared with models obtained from the "status" variable alone (Ab colonization/infection), SAPS II, and APACHE II scores. ROC curves were built to identify the best cut-off for each model.
Results: Ab infection status, use of penicillin within 90 days prior to ward admission, acidosis, Glasgow Coma Scale, blood pressure, hemoglobin and use of NIV entered the logistic regression model. Our model was confirmed to have a better sensitivity (63%), specificity (85%) and accuracy (80%) than the other models.
Conclusion: Our predictive mortality model demonstrated to be a reliable and feasible model to predict mortality in Ab infected/colonized hospitalized patients.
Keywords: Acinetobacter baumannii; Acinetobacter baumannii mortality; Colonization; Infection; Multidrug- resistance; Predictive mortality model.
© 2024. The Author(s).
Conflict of interest statement
all the authors declare they have no conflict of interest.
Figures
Similar articles
-
Incidence, risk factors, and outcome of multidrug-resistant Acinetobacter baumannii acquisition during an outbreak in a burns unit.J Hosp Infect. 2017 Nov;97(3):226-233. doi: 10.1016/j.jhin.2017.07.020. Epub 2017 Jul 25. J Hosp Infect. 2017. PMID: 28751010
-
Risk factors for bacteremic pneumonia and mortality (28-day mortality) in patients with Acinetobacter baumannii bacteremia.BMC Infect Dis. 2024 Apr 26;24(1):448. doi: 10.1186/s12879-024-09335-8. BMC Infect Dis. 2024. PMID: 38671347 Free PMC article.
-
Multidrug and carbapenem-resistant Acinetobacter baumannii infections: Factors associated with mortality.Med Clin (Barc). 2012 May 26;138(15):650-5. doi: 10.1016/j.medcli.2011.06.024. Epub 2011 Nov 16. Med Clin (Barc). 2012. PMID: 22093403
-
Nosocomial bacteremia due to Acinetobacter baumannii. Clinical features, epidemiology, and predictors of mortality.Medicine (Baltimore). 1995 Nov;74(6):340-9. doi: 10.1097/00005792-199511000-00004. Medicine (Baltimore). 1995. PMID: 7500897 Review.
-
Impact of healthcare-associated infections on mortality of hospitalized patients with COVID-19: a systematic review.Cien Saude Colet. 2025 Feb;30(2):e01112023. doi: 10.1590/1413-81232025302.01112023. Epub 2023 Nov 11. Cien Saude Colet. 2025. PMID: 39936665
Cited by
-
Prevalence and characteristics of tigecycline- and carbapenem-resistant adeN-truncated Acinetobacter baumannii: a genomic epidemiological analysis.Antimicrob Agents Chemother. 2025 Jun 4;69(6):e0184324. doi: 10.1128/aac.01843-24. Epub 2025 Apr 23. Antimicrob Agents Chemother. 2025. PMID: 40265940 Free PMC article.
References
-
- (CDC), C. f. D. C. a. P. Antibiotic Resistance Threats in the United States (2013) https://www.cdc.gov/drugresistance/pdf/ar-threats-2013-508.pdf
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources